GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach